The University of Southampton
University of Southampton Institutional Repository

Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial

Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial
Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial
Essentials
Nonacog beta pegol is a recombinant glycoPEGylated factor IX with an extended half‐life.
This phase 3 trial investigated its safety/efficacy in previously treated hemophilia B boys ≤ 12 years.
A 40 IU kg−1 dose provided effective once‐weekly prophylaxis and hemostasis when used to treat bleeds.
Nonacog beta pegol was well tolerated in previously treated boys ≤ 12 years with hemophilia B.
1538-7933
1521-1529
Carcao, M.
c2f20802-3c85-42d8-83a1-0cb9da2876a7
Zak, M.
217ec69e-e634-4f7d-994e-287e48f7a3ae
Abdul Karim, F.
7a385b5a-196e-4677-9f44-a398969cfdd9
Hanabusa, H.
9b921f9c-78f4-48e5-9128-5d9ef3571e43
Kearney, S.
8ea908f6-178a-4234-896f-6d06dd4a0842
Lu, M.-y.
db9b219e-d19f-4246-9860-04b103a87e4c
Persson, P.
c6d3dd61-8524-453d-849d-ffa7bbafc403
Rangarajan, S.
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Santagostino, E.
43deb3c2-fa5c-4d17-a8e5-960a9119f636
Carcao, M.
c2f20802-3c85-42d8-83a1-0cb9da2876a7
Zak, M.
217ec69e-e634-4f7d-994e-287e48f7a3ae
Abdul Karim, F.
7a385b5a-196e-4677-9f44-a398969cfdd9
Hanabusa, H.
9b921f9c-78f4-48e5-9128-5d9ef3571e43
Kearney, S.
8ea908f6-178a-4234-896f-6d06dd4a0842
Lu, M.-y.
db9b219e-d19f-4246-9860-04b103a87e4c
Persson, P.
c6d3dd61-8524-453d-849d-ffa7bbafc403
Rangarajan, S.
9a5e4c7e-55ba-4a3a-b5f6-f1e269d927c3
Santagostino, E.
43deb3c2-fa5c-4d17-a8e5-960a9119f636

Carcao, M., Zak, M., Abdul Karim, F., Hanabusa, H., Kearney, S., Lu, M.-y., Persson, P., Rangarajan, S. and Santagostino, E. (2016) Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial. Journal of Thrombosis and Haemostasis, 14 (8), 1521-1529. (doi:10.1111/jth.13360).

Record type: Article

Abstract

Essentials
Nonacog beta pegol is a recombinant glycoPEGylated factor IX with an extended half‐life.
This phase 3 trial investigated its safety/efficacy in previously treated hemophilia B boys ≤ 12 years.
A 40 IU kg−1 dose provided effective once‐weekly prophylaxis and hemostasis when used to treat bleeds.
Nonacog beta pegol was well tolerated in previously treated boys ≤ 12 years with hemophilia B.

This record has no associated files available for download.

More information

Accepted/In Press date: 12 April 2016
e-pub ahead of print date: 13 May 2016
Published date: 1 August 2016

Identifiers

Local EPrints ID: 442893
URI: http://eprints.soton.ac.uk/id/eprint/442893
ISSN: 1538-7933
PURE UUID: 54921e88-946a-4557-be18-482c006643ce
ORCID for S. Rangarajan: ORCID iD orcid.org/0000-0001-7367-133X

Catalogue record

Date deposited: 30 Jul 2020 16:31
Last modified: 01 Jul 2022 02:05

Export record

Altmetrics

Contributors

Author: M. Carcao
Author: M. Zak
Author: F. Abdul Karim
Author: H. Hanabusa
Author: S. Kearney
Author: M.-y. Lu
Author: P. Persson
Author: S. Rangarajan ORCID iD
Author: E. Santagostino

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×